AUSTRALIA: A groundbreaking innovation from James Cook University (JCU) is set to transform biomedical research worldwide. Scientists have developed a world-first, instrument-free method to study protein–DNA interactions for less than $5 per test, potentially accelerating drug discovery, cancer research, and biotechnology while making advanced research accessible globally.
Published open-access in Nucleic Acids Research, the new platform, called R-PNAI-T, compresses what traditionally required million-dollar instruments or radioactive facilities and hours of labor into a rapid lateral-flow dipstick test delivering results in minutes.
A lab on a strip
Associate Prof. Patrick Schaeffer, a protein–DNA interaction specialist with over 25 years’ experience, described the achievement as “the most significant achievement of my career.”
“We turned an entire lab process into a test strip. Instead of having days of work to do an experiment, you can have a rapid test-like system that can do it in about 15 minutes.”
Dr Casey Toft led the research and development of the platform, validating its core technology. Dr Alanna Sorenson tested it against a bacterial drug target, and Ms Holly Radford applied the platform to characterise the initiator protein and origin of replication of Burkholderia pseudomallei, the causative agent of melioidosis.
The platform repurposes green fluorescent protein (GFP) to detect protein–DNA binding even in crude cell samples, eliminating the need for complex purification or specialized infrastructure.
“You literally can just burst open the cells and test specifically for that protein–DNA interaction. As a bonus, we have the advantage of being able to do it in crude samples,” Schaeffer said.
Breaking barriers in research
Protein–DNA interactions are central to cancer, infectious disease, genetic disorders, and biotechnology applications. Until now, characterizing these interactions relied on high-end platforms such as surface plasmon resonance, advanced calorimetry, or dedicated radioactive facilities, often confined to specialized centers.
“Let’s imagine everyone is thinking about this instrument that is super expensive, super hard to use and long-winded, and really, no one wants to use it,” Schaeffer explained. “Then someone comes along and says instead of all that stress, you can have a rapid test-strip system.”
Despite its simplicity, R-PNAI-T matches, and in some cases exceeds, the sensitivity of flagship biophysical instruments.
“We have gotten test lines appearing at concentrations that, in the high-end machine, you would see nothing,” he said. “We have pretty much beaten the sensitivity of the million-dollar instruments.”
Implications for drug discovery and biotechnology
Beyond basic research, the platform is poised to accelerate drug discovery by enabling rapid target engagement studies, confirming whether candidate drugs directly affect the protein–DNA interactions they are designed to block.
“These days, a drug does not go to market without target engagement studies,” Schaeffer said. “We now have a system that allows researchers interested in protein–DNA interactions to do this super easily.”
Democratizing global research
Assoc Prof Schaeffer emphasized that resource-limited laboratories could now participate in high-end biomedical research:
“Being in a resource-limited environment, like regional areas with no experts around, you need to turn technologies into simple, bulletproof and robust systems that anyone can use.”
The method has been published open-access and without patent restrictions to maximize global uptake and impact, signaling a potential revolution in biotechnology, cancer research, and drug discovery worldwide.
Stay connected with Medical News Pakistan
CLICK HERE TO JOIN our WhatsApp Community for the latest health updates, life-saving medical news, and expert guidance straight to your phone.